Research analysts at StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the medical research company’s stock.
Accelerate Diagnostics Price Performance
Shares of AXDX stock opened at $2.00 on Tuesday. The stock has a market cap of $44.07 million, a PE ratio of -0.49 and a beta of 0.57. The stock has a 50-day moving average of $1.40 and a 200-day moving average of $1.17. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $7.25.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The firm had revenue of $2.99 million during the quarter, compared to the consensus estimate of $3.00 million. As a group, research analysts anticipate that Accelerate Diagnostics will post -2.14 earnings per share for the current year.
Institutional Trading of Accelerate Diagnostics
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Further Reading
- Five stocks we like better than Accelerate Diagnostics
- What is a support level?
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- Consumer Staples Stocks, Explained
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- High Flyers: 3 Natural Gas Stocks for March 2022
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.